{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:44:18Z","timestamp":1788335058014,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:00:00Z","timestamp":1736640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:00:00Z","timestamp":1736640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Gen Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Seizure threshold increases with age and the frequency of electroconvulsive therapy (ECT). Therefore, therapeutic seizures can be difficult to induce, even at maximum stimulus charge with available ECT devices. Such cases are known as difficult-to-induce-seizures electroconvulsive therapy cases (DECs). However, no clinical guidelines exist for DECs; thus, clinicians often face difficulties determining treatment strategies. This study aimed to obtain a consensus among clinical experts regarding the treatment of DECs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We asked Japanese ECT experts to rate 14 approaches under six conditions of DECs on a 9-point Likert scale (1\u2009=\u2009\u201cdisagree\u201d to 9\u2009=\u2009\u201cagree\u201d). Based on responses from 195 experts, the approaches were classified as first-line (95% confidence interval mean\u2009\u2265\u20096.5), second-line (mean, 3.5\u20136.5), or third-line strategies (mean\u2009&lt;\u20093.5). Approaches rated 9 points by at least 50% of the respondents were considered \u201ctreatments of choice.\u201d<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>To avoid difficult seizure induction, dose reduction of benzodiazepine receptor agonist (BZRA) (8.33\u2009\u00b1\u20091.25), dose reduction or discontinuation of antiepileptic drugs (AEDs) or other drugs that may make seizure induction difficult (8.16\u2009\u00b1\u20091.18), and ensure hyperventilation (7.95\u2009\u00b1\u20091.47) were classified as treatments of choice. First-line treatment strategies were BRZA discontinuation (7.89\u2009\u00b1\u20091.45), stimulation timing adjustment (7.00\u2009\u00b1\u20092.00), and anesthetic dose reduction (6.93\u2009\u00b1\u20091.94). Dose reduction or discontinuation of AEDs or other drugs that might make seizure induction difficult and ensure hyperventilation were the treatments of choice across all patient conditions. The results of rating approaches for patients with mood disorders and schizophrenia were similar, with differences observed among the approaches for patients with catatonia, high risk of cognitive impairment, and cardiovascular events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>ECT expert recommendations are useful and can assist in clinical decision-making. Our results suggest that while some strategies are applicable across all conditions, others should be tailored to meet the specific needs of patients. These recommendations should be further evaluated in future clinical studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12991-024-00543-9","type":"journal-article","created":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T19:43:26Z","timestamp":1736711006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Approaches for difficult-to-induce-seizures electroconvulsive therapy cases (DEC): a Japanese expert consensus"],"prefix":"10.1186","volume":"24","author":[{"given":"Yoshiteru","family":"Takekita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kurimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuatsu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Takebayash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Expert Consensus Development Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Electroconvulsive Therapy Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japanese Society of General Hospital Psychiatry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,12]]},"reference":[{"issue":"7","key":"543_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1056\/NEJMra2034954","volume":"386","author":"RT Espinoza","year":"2022","unstructured":"Espinoza RT, Kellner CH. Electroconvulsive therapy. N Engl J Med. 2022;386(7):667\u201372.","journal-title":"N Engl J Med"},{"issue":"2","key":"543_CR2","first-page":"171","volume":"10","author":"MD Beale","year":"1994","unstructured":"Beale MD, Kellner CH, Pritchett JT, Bernstein HJ, Burns CM, Knapp R. Stimulus dose-titration in ECT: a 2-year clinical experience. Convuls Ther. 1994;10(2):171\u20136.","journal-title":"Convuls Ther"},{"issue":"1","key":"543_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00124509-200003000-00002","volume":"16","author":"LS Boylan","year":"2000","unstructured":"Boylan LS, Haskett RF, Mulsant BH, Greenberg RM, Prudic J, Spicknall K, et al. Determinants of seizure threshold in ECT: benzodiazepine use, anesthetic dosage, and other factors. J ECT. 2000;16(1):3\u201318.","journal-title":"J ECT"},{"issue":"2","key":"543_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/YCT.0b013e31815f65b9","volume":"24","author":"M Fink","year":"2008","unstructured":"Fink M, Petrides G, Kellner C, Mueller M, Knapp R, Husain MM, et al. Change in seizure threshold during electroconvulsive therapy. J ECT. 2008;24(2):114\u20136.","journal-title":"J ECT"},{"issue":"4","key":"543_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/archpsyc.1987.01800160067009","volume":"44","author":"H Sackeim","year":"1987","unstructured":"Sackeim H, Decina P, Prohovnik I, Malitz S. Seizure threshold in electroconvulsive therapy. Effects of sex, age, electrode placement, and number of treatments. Arch Gen Psychiatry. 1987;44(4):355\u201360.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"543_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/00124509-200009000-00004","volume":"16","author":"AI Scott","year":"2000","unstructured":"Scott AI, Boddy H. The effect of repeated bilateral electroconvulsive therapy on seizure threshold. J ECT. 2000;16(3):244\u201351.","journal-title":"J ECT"},{"issue":"3","key":"543_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jad.2009.07.011","volume":"124","author":"CK Loo","year":"2010","unstructured":"Loo CK, Kaill A, Paton P, Simpson B. The difficult-to-treat electroconvulsive therapy patient\u2014strategies for augmenting outcomes. J Affect Disord. 2010;124(3):219\u201327.","journal-title":"J Affect Disord"},{"issue":"3","key":"543_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/YCT.0b013e3181e48143","volume":"26","author":"C Loo","year":"2010","unstructured":"Loo C, Simpson B, MacPherson R. Augmentation strategies in electroconvulsive therapy. J ECT. 2010;26(3):202\u20137.","journal-title":"J ECT"},{"issue":"145","key":"543_CR9","first-page":"5","volume":"35","author":"JO Ottosson","year":"1960","unstructured":"Ottosson JO. Experimental studies of the mode of action of electroconvulsive therapy: introduction. Acta Psychiatr Scand Suppl. 1960;35(145):5\u20136.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"2","key":"543_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/YCT.0000000000000274","volume":"32","author":"A Minelli","year":"2016","unstructured":"Minelli A, Abate M, Zampieri E, Gainelli G, Trabucchi L, Segala M, et al. Seizure adequacy markers and the prediction of electroconvulsive therapy response. J ECT. 2016;32(2):88\u201392.","journal-title":"J ECT"},{"issue":"1\u20132","key":"543_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.eplepsyres.2011.08.007","volume":"97","author":"H Takano","year":"2011","unstructured":"Takano H, Motohashi N, Uema T, Ogawa K, Ohnishi T, Nishikawa M, et al. Differences in cerebral blood flow between missed and generalized seizures with electroconvulsive therapy: a positron emission tomographic study. Epilepsy Res. 2011;97(1\u20132):225\u20138.","journal-title":"Epilepsy Res"},{"issue":"8","key":"543_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00406-009-0011-7","volume":"259","author":"JA van Waarde","year":"2009","unstructured":"van Waarde JA, Verwey B, van der Mast RC. Meta-analysis of initial seizure thresholds in electroconvulsive therapy. Eur Arch Psychiatry Clin Neurosci. 2009;259(8):467\u201374.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"543_CR13","first-page":"419","volume":"34","author":"M Takebayashi","year":"2022","unstructured":"Takebayashi M. Report of the electroconvulsive therapy committee. Jpn J Gen Hosp Psychiatry. 2022;34(4):419\u201321.","journal-title":"Jpn J Gen Hosp Psychiatry"},{"issue":"3","key":"543_CR14","first-page":"286","volume":"33","author":"T Suwa","year":"2021","unstructured":"Suwa T, Yasuda K, Kawashima H, Aoki N, Uchinuma N, Takekita Y, et al. A current survey and literature review of seizure induction difficulties during electroconvulsive therapy and how to deal with them. Jpn J Gen Hosp Psychiatry. 2021;33(3):286\u201397.","journal-title":"Jpn J Gen Hosp Psychiatry"},{"issue":"8","key":"543_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/bdi.12959","volume":"22","author":"H Sakurai","year":"2020","unstructured":"Sakurai H, Kato M, Yasui-Furukori N, Suzuki T, Baba H, Watanabe K, et al. Pharmacological management of bipolar disorder: Japanese expert consensus. Bipolar Disord. 2020;22(8):822\u201330.","journal-title":"Bipolar Disord"},{"issue":"1","key":"543_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00131746-200301000-00004","volume":"9","author":"MH Allen","year":"2003","unstructured":"Allen MH, Currier GW, Hughes DH, Docherty JP, Carpenter D, Ross R. Treatment of behavioral emergencies: a summary of the expert consensus guidelines. J Psychiatr Pract. 2003;9(1):16\u201338.","journal-title":"J Psychiatr Pract"},{"issue":"8","key":"543_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00406-016-0670-0","volume":"266","author":"Y Takekita","year":"2016","unstructured":"Takekita Y, Suwa T, Sunada N, Kawashima H, Fabbri C, Kato M, et al. Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci. 2016;266(8):703\u201317.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"543_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/YCT.0000000000000632","volume":"36","author":"NJ Ainsworth","year":"2020","unstructured":"Ainsworth NJ, Sepehry AA, Vila-Rodriguez F. Effects of ketamine anesthesia on efficacy, tolerability, seizure response, and neurocognitive outcomes in electroconvulsive therapy: a comprehensive meta-analysis of double-blind randomized controlled trials. J ECT. 2020;36(2):94\u2013105.","journal-title":"J ECT"},{"issue":"1","key":"543_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/npr2.12039","volume":"39","author":"M Eda","year":"2019","unstructured":"Eda M, Matsuki R. When to switch from bilateral to unilateral electroconvulsive therapy: a simple way to elicit seizures in high seizure threshold cases. Neuropsychopharmacol Rep. 2019;39(1):36\u201340.","journal-title":"Neuropsychopharmacol Rep"},{"key":"543_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/NDT.S160093","volume":"14","author":"H Kawashima","year":"2018","unstructured":"Kawashima H, Kobayashi Y, Suwa T, Murai T, Yoshioka R. Successful switch from bilateral brief pulse to right unilateral ultrabrief pulse electroconvulsive therapy after failure to induce seizures. Neuropsychiatr Dis Treat. 2018;14:607\u201310.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"543_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jclinane.2019.05.006","volume":"58","author":"G Guerrier","year":"2019","unstructured":"Guerrier G, Gianni MA. The effectiveness of BIS monitoring during electro-convulsive therapy: a systematic review and meta-analysis. J Clin Anesth. 2019;58:100\u20134.","journal-title":"J Clin Anesth"},{"issue":"2","key":"543_CR22","first-page":"95","volume":"9","author":"A Calev","year":"1993","unstructured":"Calev A, Fink M, Petrides G, Francis A, Fochtmann L. Caffeine pretreatment enhances clinical efficacy and reduces cognitive effects of electroconvulsive therapy. Convuls Ther. 1993;9(2):95\u2013100.","journal-title":"Convuls Ther"},{"issue":"5","key":"543_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1176\/ajp.147.5.579","volume":"147","author":"CE Coffey","year":"1990","unstructured":"Coffey CE, Figiel GS, Weiner RD, Saunders WB. Caffeine augmentation of ECT. Am J Psychiatry. 1990;147(5):579\u201385.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"543_CR24","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1176\/ajp.150.10.1543","volume":"150","author":"WV McCall","year":"1993","unstructured":"McCall WV, Reid S, Rosenquist P, Foreman A, Kiesow-Webb N. A reappraisal of the role of caffeine in ECT. Am J Psychiatry. 1993;150(10):1543\u20135.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"543_CR25","first-page":"596","volume":"81","author":"MN Avramov","year":"1995","unstructured":"Avramov MN, Husain MM, White PF. The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy. Anesth Analg. 1995;81(3):596\u2013602.","journal-title":"Anesth Analg"},{"issue":"6","key":"543_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1046\/j.1440-1819.1999.00621.x","volume":"53","author":"A Sakamoto","year":"1999","unstructured":"Sakamoto A, Hoshino T, Suzuki N, Suzuki H, Kimura M, Ogawa R. Effects of propofol anesthesia on cognitive recovery of patients undergoing electroconvulsive therapy. Psychiatry Clin Neurosci. 1999;53(6):655\u201360.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"2","key":"543_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.brs.2008.03.001","volume":"1","author":"HA Sackeim","year":"2008","unstructured":"Sackeim HA, Prudic J, Nobler MS, Fitzsimons L, Lisanby SH, Payne N, et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimul. 2008;1(2):71\u201383.","journal-title":"Brain Stimul"},{"issue":"11","key":"543_CR28","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.4088\/JCP.13m08538","volume":"74","author":"HP Spaans","year":"2013","unstructured":"Spaans HP, Verwijk E, Comijs HC, Kok RM, Sienaert P, Bouckaert F, et al. Efficacy and cognitive side effects after brief pulse and ultrabrief pulse right unilateral electroconvulsive therapy for major depression: a randomized, double-blind, controlled study. J Clin Psychiatry. 2013;74(11):e1029\u201336.","journal-title":"J Clin Psychiatry"},{"key":"543_CR29","doi-asserted-by":"publisher","first-page":"19847","DOI":"10.1038\/srep19847","volume":"6","author":"G Fond","year":"2016","unstructured":"Fond G, Bennabi D, Haffen E, Brunel L, Micoulaud-Franchi JA, Loundou A, et al. A Bayesian framework systematic review and meta-analysis of anesthetic agents effectiveness\/tolerability profile in electroconvulsive therapy for major depression. Sci Rep. 2016;6:19847.","journal-title":"Sci Rep"},{"issue":"4","key":"543_CR30","first-page":"CD009763","volume":"2014","author":"P Lihua","year":"2014","unstructured":"Lihua P, Su M, Ke W, Ziemann-Gimmel P. Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression. Cochrane Database Syst Rev. 2014;2014(4):CD009763.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"543_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/YCT.0b013e3181c18901","volume":"26","author":"P Mayur","year":"2010","unstructured":"Mayur P, Bray A, Fernandes J, Bythe K, Gilbett D. Impact of hyperventilation on stimulus efficiency during the early phase of an electroconvulsive therapy course: a randomized double-blind study. J ECT. 2010;26(2):91\u20134.","journal-title":"J ECT"},{"key":"543_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jclinane.2016.11.006","volume":"37","author":"K Nishikawa","year":"2017","unstructured":"Nishikawa K, Yamakage M. Effects of the concurrent use of a reduced dose of propofol with divided supplemental remifentanil and moderate hyperventilation on duration and morphology of electroconvulsive therapy-induced electroencephalographic seizure activity: a randomized controlled trial. J Clin Anesth. 2017;37:63\u20138.","journal-title":"J Clin Anesth"},{"issue":"7","key":"543_CR33","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0006-3223(90)90597-U","volume":"27","author":"AC Pande","year":"1990","unstructured":"Pande AC, Shea J, Shettar S, Grunhaus LJ, Haskett RF. Effect of hyperventilation on seizure length during electroconvulsive therapy. Biol Psychiatry. 1990;27(7):799\u2013801.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"543_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/YCT.0b013e3181620815","volume":"24","author":"E Sawayama","year":"2008","unstructured":"Sawayama E, Takahashi M, Inoue A, Nakajima K, Kano A, Sawayama T, et al. Moderate hyperventilation prolongs electroencephalogram seizure duration of the first electroconvulsive therapy. J ECT. 2008;24(3):195\u20138.","journal-title":"J ECT"},{"issue":"8","key":"543_CR35","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1176\/ajp.147.8.1029","volume":"147","author":"HM Pettinati","year":"1990","unstructured":"Pettinati HM, Stephens SM, Willis KM, Robin SE. Evidence for less improvement in depression in patients taking benzodiazepines during unilateral ECT. Am J Psychiatry. 1990;147(8):1029\u201335.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"543_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/pcn.12225","volume":"69","author":"K Yasuda","year":"2015","unstructured":"Yasuda K, Kobayashi K, Yamaguchi M, Tanaka K, Fujii T, Kitahara Y, et al. Seizure threshold and the half-age method in bilateral electroconvulsive therapy in Japanese patients. Psychiatry Clin Neurosci. 2015;69(1):49\u201354.","journal-title":"Psychiatry Clin Neurosci"},{"key":"543_CR37","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2147\/NDT.S134503","volume":"13","author":"SW Joo","year":"2017","unstructured":"Joo SW, Joo YH, Kim CY, Lee JS. Effects of stimulus parameters on motor seizure duration in electroconvulsive therapy. Neuropsychiatr Dis Treat. 2017;13:1427\u201334.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"543_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/WNF.0000000000000429","volume":"44","author":"N Uchinuma","year":"2021","unstructured":"Uchinuma N, Yasuda K, Iwata Y, Hirata T, Uemura T, Tamaoki T, et al. Flumazenil for successful seizure induction with electroconvulsive therapy: case report and literature review. Clin Neuropharmacol. 2021;44(1):29\u201332.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"543_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/YCT.0b013e3182507752","volume":"28","author":"J Yi","year":"2012","unstructured":"Yi J, Torres J, Azner Y, Vaidya P, Schiavi A, Reti IM. Flumazenil pretreatment in benzodiazepine-free patients: a novel method for managing declining ECT seizure quality. J ECT. 2012;28(3):185\u20139.","journal-title":"J ECT"},{"issue":"1\u20133","key":"543_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jad.2010.05.008","volume":"127","author":"HS Virupaksha","year":"2010","unstructured":"Virupaksha HS, Shashidhara B, Thirthalli J, Kumar CN, Gangadhar BN. Comparison of electroconvulsive therapy (ECT) with or without anti-epileptic drugs in bipolar disorder. J Affect Disord. 2010;127(1\u20133):66\u201370.","journal-title":"J Affect Disord"},{"issue":"1","key":"543_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3109\/10401239709147770","volume":"9","author":"CA Zarate Jr","year":"1997","unstructured":"Zarate CA Jr, Tohen M, Baraibar G. Combined valproate or carbamazepine and electroconvulsive therapy. Ann Clin Psychiatry. 1997;9(1):19\u201325.","journal-title":"Ann Clin Psychiatry"},{"issue":"3","key":"543_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1017\/neu.2015.8","volume":"27","author":"S Grover","year":"2015","unstructured":"Grover S, Hazari N, Kate N. Combined use of clozapine and ECT: a review. Acta Neuropsychiatr. 2015;27(3):131\u201342.","journal-title":"Acta Neuropsychiatr"},{"issue":"3","key":"543_CR43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1176\/ajp.150.3.525a","volume":"150","author":"T Lanes","year":"1993","unstructured":"Lanes T, Ravaris CL. Prolonged ECT seizure duration in a patient taking trazodone. Am J Psychiatry. 1993;150(3):525.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"543_CR44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/jmau.jmau_19_21","volume":"10","author":"A Althagafi","year":"2022","unstructured":"Althagafi A. Effects of caffeine, theophylline, and aminophylline on electroconvulsive therapy: a review of evidence. J Microsc Ultrastruct. 2022;10(3):103\u20136.","journal-title":"J Microsc Ultrastruct"},{"key":"543_CR45","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2147\/NDT.S67121","volume":"10","author":"H Kawashima","year":"2014","unstructured":"Kawashima H, Suwa T, Murai T, Yoshioka R. Elongation of pulse width as an augmentation strategy in electroconvulsive therapy. Neuropsychiatr Dis Treat. 2014;10:2009\u201314.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"543_CR46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/02698811231158232","volume":"37","author":"JP Rogers","year":"2023","unstructured":"Rogers JP, Oldham MA, Fricchione G, Northoff G, Ellen Wilson J, Mann SC, et al. Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023;37(4):327\u201369.","journal-title":"J Psychopharmacol"},{"key":"543_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/9781119870203","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"DM Taylor","year":"2021","unstructured":"Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th ed. Hoboken: John Wiley & Sons; 2021.","edition":"14"},{"issue":"4","key":"543_CR48","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/YCT.0000000000000586","volume":"35","author":"D Bjornshauge","year":"2019","unstructured":"Bjornshauge D, Hjerrild S, Videbech P. Electroconvulsive therapy practice in the Kingdom of Denmark: a nationwide register\u2014and questionnaire-based study. J ECT. 2019;35(4):258\u201363.","journal-title":"J ECT"},{"issue":"3","key":"543_CR49","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1017\/S0033291716002737","volume":"47","author":"E Kolshus","year":"2017","unstructured":"Kolshus E, Jelovac A, McLoughlin DM. Bitemporal v. high-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials. Psychol Med. 2017;47(3):518\u201330.","journal-title":"Psychol Med."},{"issue":"4","key":"543_CR50","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00002018-199005040-00004","volume":"5","author":"MH Skinner","year":"1990","unstructured":"Skinner MH. Adverse reactions and interactions with theophylline. Drug Saf. 1990;5(4):275\u201385.","journal-title":"Drug Saf"},{"issue":"12","key":"543_CR51","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1002\/ptr.8000","volume":"37","author":"X Song","year":"2023","unstructured":"Song X, Kirtipal N, Lee S, Maly P, Bharadwaj S. Current therapeutic targets and multifaceted physiological impacts of caffeine. Phytother Res. 2023;37(12):5558\u201398.","journal-title":"Phytother Res"},{"issue":"10202","key":"543_CR52","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351.","journal-title":"Lancet"},{"key":"543_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2020.101950","volume":"50","author":"G Kanniah","year":"2020","unstructured":"Kanniah G, Kumar S. Clozapine associated cardiotoxicity: Issues, challenges and way forward. Asian J Psychiatr. 2020;50: 101950.","journal-title":"Asian J Psychiatr"},{"issue":"4","key":"543_CR54","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40261-021-01000-1","volume":"41","author":"C Rognoni","year":"2021","unstructured":"Rognoni C, Bertolani A, Jommi C. Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects. Clin Drug Investig. 2021;41(4):303\u201319.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"543_CR55","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ajem.2016.03.005","volume":"34","author":"TA Bagwell","year":"2016","unstructured":"Bagwell TA, Abramo TJ, Albert GW, Orsborn JW, Storm EA, Hobart-Porter NW, et al. Cerebral oximetry with blood volume index and capnography in intubated and hyperventilated patients. Am J Emerg Med. 2016;34(6):1102\u20137.","journal-title":"Am J Emerg Med"},{"issue":"4","key":"543_CR56","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/00000542-199810000-00006","volume":"89","author":"S Kazmaier","year":"1998","unstructured":"Kazmaier S, Weyland A, Buhre W, Stephan H, Rieke H, Filoda K, et al. Effects of respiratory alkalosis and acidosis on myocardial blood flow and metabolism in patients with coronary artery disease. Anesthesiology. 1998;89(4):831\u20137.","journal-title":"Anesthesiology"},{"key":"543_CR57","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00000542-196003000-00001","volume":"21","author":"K Sugioka","year":"1960","unstructured":"Sugioka K, Davis DA. Hyperventilation with oxygen-a possible cause of cerebral hypoxia. Anesthesiology. 1960;21:135\u201343.","journal-title":"Anesthesiology"},{"issue":"7","key":"543_CR58","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5348\/ijcri-2012-07-147-CR-8","volume":"3","author":"H Inomata","year":"2012","unstructured":"Inomata H, Harima H, Itokawa M. A case of schizophrenia successfully treated by m-ECT using \u201clong\u201d brief pulse. International Journal of Case Reports and Images. 2012;3(7):30\u20134.","journal-title":"International Journal of Case Reports and Images"},{"issue":"1","key":"543_CR59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/npr2.12224","volume":"42","author":"H Katagai","year":"2022","unstructured":"Katagai H, Yasui-Furukori N, Kawashima H, Suwa T, Tsushima C, Sato Y, et al. Serial case report of high seizure threshold patients that responded to the lengthening of pulse width in ECT. Neuropsychopharmacol Rep. 2022;42(1):105\u20138.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"5","key":"543_CR60","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/j.1360-0443.2011.03686.x","volume":"107","author":"M Nielsen","year":"2012","unstructured":"Nielsen M, Hansen EH, Gotzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction. 2012;107(5):900\u20138.","journal-title":"Addiction"},{"issue":"4","key":"543_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0165-0327(93)90051-K","volume":"27","author":"BN Gangadhar","year":"1993","unstructured":"Gangadhar BN, Janakiramaiah N, Subbakrishna DK, Praveen J, Reddy AK. Twice versus thrice weekly ECT in melancholia: a double-blind prospective comparison. J Affect Disord. 1993;27(4):273\u20138.","journal-title":"J Affect Disord"}],"container-title":["Annals of General Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12991-024-00543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12991-024-00543-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12991-024-00543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T20:31:34Z","timestamp":1736713894000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals-general-psychiatry.biomedcentral.com\/articles\/10.1186\/s12991-024-00543-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,12]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1186\/s12991-024-00543-9","relation":{},"ISSN":["1744-859X"],"issn-type":[{"value":"1744-859X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,12]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board for Clinical Research of Kansai Medical University Medical Center (2022275). Informed consent was obtained via the questionnaire from the experts regarding their participation in the research, provision of research-related information, protection of personal information, management of information, and disclosure of information regarding the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. We have had the following interests over the past three years: YT has received grant funding from the Japan Society for the Promotion of Science and speaker\u2019s honoraria from Meiji-Seika Pharma, Sumitomo Pharma, Janssen Pharmaceutical, Otsuka, Eisai, Lundbeck, Daiichi-Sankyo, Takeda Pharmaceutical, UCB Japan, Novartis, Teijin Pharma, Nippon Boehringer Ingelheim, and Mitsubishi Tanabe Pharma. TS received grant funding from Shionogi & Co., Ltd. and speaker\u2019s honoraria from EA Pharma Co. Ltd., Otsuka, Lundbeck, Merck Sharp & Dohme, Sumitomo Pharma, Takeda Pharmaceutical, and Tsumura & Co. KY has received speaker honoraria from Sumitomo Pharma, Otsuka, Eisai, and Viatris. WO received grant funding from the Japan Society for the Promotion of Science and speaker honoraria from Otsuka, Viatris, and BioGaia. HK has received speaker honoraria from Otsuka, Sumitomo Pharma, and Lundbeck in Japan. NK has received speaker honoraria from Sumitomo Pharma, Janssen Pharmaceutical, Otsuka, Lundbeck, Daiichi-Sankyo, Takeda Pharmaceutical, and MSD. TT received a grant from the Japan Society for the Promotion of Science and honorariums from Takeda Pharmaceutical, Otsuka Pharmaceutical, Meiji Seika Pharma, Shionogi Pharma, Yoshitomiyakuhin, Sumitomo Pharma, Kyowa Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Mylan EPD, Mitsubishi Tanabe Pharma, Viatris, Mochida Pharmaceutical, Janssen Pharmaceutical, TEIJIN PHARMA, and Lundbeck, Japan. TN received research grant funding from the Japan Agency for Medical Research and Development (23fk0108586s0101 and 24dk0307125h0001), Senshin Medical Research Foundation, XNef, and Inter Reha and speaker honoraria from EA Pharma, Janssen, Lundbeck, MSD, Otsuka, Sumitomo, and Takeda. NA has received grant funding from the Japan Society for the Promotion of Science and speaker\u2019s honoraria from Meiji-Seika Pharma, Lundbeck, and Sumitomo Pharma outside the submitted work. KW has received speaker honoraria from Sumitomo Pharma, Otsuka, Eisai, Takeda Pharmaceutical, MSD, Viatris, and Mitsubishi Tanabe Pharma. Ken Inada received personal fees from Daiichi-Sankyo, Eisai, Eli Lilly, Janssen, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida, MSD, Nipro, Novartis, Otsuka, Pfizer, Shionogi, Sumitomo Pharma, Yoshitomiyakuhin, Viatris, and he received research grant support from Mochida, Otsuka and Sumitomo pharma in the last three years. MT received grant funding from Japan Society for the Japan Society for the Promotion of Science, Otsuka, Eisai, and Daiichi-Sankyo, and honoraria of speakers and chairpersons from Meiji-Seika Pharma, Sumitomo Pharma, Janssen Pharmaceutical, Otsuka, Eisai, Lundbeck, Daiichi-Sankyo, Takeda Pharmaceutical, and Teijin Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}